Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

Although combination therapy including chemotherapy and immune checkpoint inhibitors (ICIs) improves overall survival (OS) of patients with non-small-cell lung cancer (NSCLC), there is a higher incidence of adverse events and treatment discontinuation. Since programmed death-ligand 1 (PD-L1) could n...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chian-Wei, Lin, Chien-Yu, Tsai, Jeng-Shiuan, Lin, Chia-Yin, Chang, Chao-Chun, Yen, Yi-Ting, Tseng, Yau-Lin, Su, Po-Lan, Lin, Chien-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475717/
https://www.ncbi.nlm.nih.gov/pubmed/37671055
http://dx.doi.org/10.3389/fonc.2023.1238876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475717/
https://www.ncbi.nlm.nih.gov/pubmed/37671055
http://dx.doi.org/10.3389/fonc.2023.1238876

Ejemplares similares